62 related articles for article (PubMed ID: 11185668)
1. Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function.
St Peter JV; Lambrecht LJ; Gunderson BW; Andersen SA; Gallagher SC; Swan SK
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1470-5. PubMed ID: 11185668
[TBL] [Abstract][Full Text] [Related]
2. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Cheng JW; Charland SL; Goldfarb S; Spinler SA
Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of rizatriptan in healthy elderly subjects.
Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
[TBL] [Abstract][Full Text] [Related]
10. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
11. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
14. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
15. A study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2007 Jan; 90(1):160-6. PubMed ID: 17621748
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of pioglitazone in Thai healthy subjects.
Wittayalertpanya S; Chompootaweep S; Thaworn N
J Med Assoc Thai; 2006 Dec; 89(12):2116-22. PubMed ID: 17214065
[TBL] [Abstract][Full Text] [Related]
17. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
19. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
20. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
